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2. ABSTRACT 26 
Neprilysin is a widely-expressed membrane-bound metalloprotease which binds and 27 
cleaves a variety of peptides including vasodilators, natriuretics and diuretics. Higher 28 
levels of neprilysin result in hypertension, a cardinal feature of the placental disease 29 
preeclampsia. Syncytiotrophoblast-derived extracellular vesicles, comprising 30 
microvesicles and exosomes are released into the peripheral circulation in 31 
pregnancy and are postulated as a key mechanism coupling placental dysfunction 32 
and maternal phenotype in preeclampsia. We aimed to determine whether higher 33 
levels of active neprilysin are found in syncytiotrophoblast-derived extracellular 34 
vesicles in preeclampsia compared to normal pregnancy. 35 
 36 
Using immunostaining and Western blotting, we first demonstrated that neprilysin 37 
levels are greater not only in preeclampsia placental tissue, but also in 38 
syncytiotrophoblast-derived microvesicles and exosomes isolated from preeclampsia 39 
placentas (p<0.05, n=5). We confirmed placental origin using antibody-coated 40 
magnetic beads to isolate neprilysin-bound vesicles, finding that they stain for 41 
placental alkaline phosphatase. Neprilysin on syncytiotrophoblast-derived 42 
extracellular vesicles is active and inhibited by thiorphan (p<0.01, n=3; specific 43 
inhibitor). Syncytiotrophoblast-derived microvesicles, isolated from peripheral 44 
plasma, demonstrated higher neprilysin expression in preeclampsia using flow 45 
cytometry (n=8, p<0.05). We isolated plasma exosomes using size-exclusion 46 
chromatography and showed greater neprilysin activity in preeclampsia (n=8, 47 
p<0.05).  48 
 49 
 3 
These findings show that the placenta releases active neprilysin into the maternal 50 
circulation on syncytiotrophoblast-derived extracellular vesicles, at significantly 51 
greater levels in preeclampsia. Neprilysin has pathological roles in hypertension, 52 
heart failure and amyloid deposition, all of which are features of preeclampsia. 53 
Circulating syncytiotrophoblast-derived extracellular vesicle-bound neprilysin thus 54 
may contribute to the pathogenesis of this disease.  55 
 56 
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3. TEXT 59 
A) INTRODUCTION 60 
Preeclampsia (PE) is a pregnancy-specific syndrome characterised by new onset 61 
hypertension and proteinuria in the second half of pregnancy, but often associated 62 
with more widespread organ dysfunction[1,2]. Worldwide PE occurs in 2-8% of 63 
pregnancies and it is one of the major global causes of maternal and fetal 64 
mortality[3]. A pathological process of systemic vascular inflammation and 65 
endothelial activation in PE can affect multiple organs, including: the peripheral 66 
vasculature (hypertension), liver (hepatocellular necrosis), kidneys (acute glomerular 67 
dysfunction or, more rarely, tubular or renal cortical necrosis), central nervous 68 
system (seizures and intracerebral haemorrhage) and the heart (left ventricular 69 
hypertrophy with diastolic dysfunction)[4–7]. The proximate cause of PE is the 70 
placenta since the disease is pregnancy specific, can occur in molar pregnancies or 71 
trophoblast tumours (where no fetal tissue is present) and resolves only following 72 
delivery of the placenta[8]. Poor placentation in early pregnancy, specifically with 73 
inadequate spiral artery remodelling appears to predate the clinical syndrome of 74 
PE[9]. The mechanism by which a chronically hypoxic placenta causes such diffuse 75 
multi-organ dysfunction in the mother remains elusive.  76 
 77 
The syncytiotrophoblast (STB) is the layer of placenta in direct contact with maternal 78 
blood, with a total surface area of up to 10 m2[10]. Up to 3 grams per day of 79 
extracellular vesicles (EV) are released from STB into the maternal circulation at 80 
term. Significantly higher levels of STBEV are found in the peripheral blood of 81 
women with PE than those with normal pregnancies (NP)[11]. It is consequently 82 
postulated that STBEV could be the missing link between the placental dysfunction 83 
 5 
and later clinical associated maternal syndrome in PE[12].  To explore this 84 
hypothesis we performed a proteomic analysis of STBEV released during dual-lobe 85 
placental perfusion from 8 women with PE and 7 women with NP (unpublished data). 86 
This showed that neprilysin was upregulated in STBEV from women with PE. 87 
Neprilysin (NEP), also known as CD10, CALLA (Common Acute Lymphocytic 88 
Leukemia Antigen) or MME (membrane metallo-endopeptidase) is a zinc 89 
metalloendopeptidase with a wide tissue distribution. It cleaves and inactivates a 90 
variety of bioactive peptides[13]. NEP inhibitors have recently attracted attention in 91 
cardiovascular medicine as a novel treatment for heart failure[14]. By inhibiting the 92 
degradation of endogenous vasoactive peptides, NEP inhibitors promote 93 
vasodilatation and prevent sodium retention and consequently counter pathological 94 
cardiac remodelling[15].  95 
In previous studies Li and colleagues reported greater expression of placental NEP 96 
in PE pregnancies, localised to the surface and cytoplasm of trophoblast cells[16]. 97 
Buhimschi et al found increased NEP in the urine of women with severe PE[17]. No 98 
group has previously reported on NEP expression and activity in STB-EV. 99 
We hypothesised that NEP expression and activity are upregulated in STB-EV from 100 
women with PE compared to NP and might contribute to the clinical syndrome of PE. 101 
 102 
 103 
 104 
 105 
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B) METHODS 106 
The raw data that support the findings of this study are available from the 107 
corresponding author upon reasonable request. 108 
Human subjects 109 
Approval for this project was granted by the Central Oxfordshire Research Ethics 110 
Committee (07/H0607/74 and 07/H0606/148). Women recruited for this study 111 
provided written informed consent; clinical characteristics are described in Table 1. 112 
According to the criteria defined by the International Society for the Study of 113 
Hypertension in Pregnancy (ISSHP), de novo hypertension (blood pressure >140/90 114 
mmHg) and proteinuria (>300 mg/day) after gestational week 20 was used to 115 
diagnose PE. Women with NP had singleton pregnancies and no evidence of PE or 116 
previous hypertensive disorders.  117 
Peripheral blood was taken from the left antecubital fossa and collected in 4.5 mL 118 
citrate tubes using a 21-gauge needle. Samples were centrifuged at 1,500 x g for 15 119 
minutes and the platelet poor plasma (PPP) was collected.  Aliquots of 1 mL PPP 120 
were stored at –80°C in preparation for flow cytometry analysis and EV isolation. 121 
PPP samples collected from women with PE and NP were matched according to 122 
gestational age. Placentae were collected at the time of elective caesarean section 123 
(a different cohort of patients).  124 
Immunohistochemistry  125 
Paraffin-embedded placental tissue sections from NP and PE placentas were cut at 126 
8 μm and attached onto slides. Tissues were stored at room temperature until use. 127 
Sections were heated at 62°C for 30 minutes, immersed in Histo-Clear (National 128 
Diagnostics, Atlanta, USA) and rehydrated using ethanol. Antigens were retrieved 129 
 7 
using 10 mM sodium citrate buffer and endogenous peroxidase activity was blocked 130 
with 3% v/v hydrogen peroxide. The sections were treated with blocking agent 10% 131 
v/v fetal calf serum in PBS for 1 hour and incubated overnight at 4°C with mouse 132 
monoclonal antibodies: anti-NEP (1:25, ab951; Abcam, Cambridge, UK) and anti-133 
IgG1 (1:25, 400153; BioLegend, California, USA). VECTASTAIN® Elite® ABC Kit 134 
(Vector Laboratories, Peterborough, UK) reagents were used to incubate sections at 135 
room temperature in biotinylated horse anti-mouse IgG secondary antibody for 1 136 
hour and enhancer reagent for 30 minutes. Exposure to DAB substrate kit (Vector 137 
Laboratories) was used to detect specific antibody binding and nuclei were stained 138 
with Shandon™ Harris Hematoxylin (Thermo Fisher Scientific, Massachusetts, 139 
USA). Sections were dehydrated using ethanol, mounted with Depex (VWR, 140 
Philadelphia, USA) and imaged using a Leica DM2500 optical microscope (Leica 141 
Microsystems, Wetzlar, Germany) with a Micropublisher 5.0 RTV camera system 142 
(QImaging, Surrey, Canada).  143 
Isolation and characterisation of STBEV 144 
Placental perfusate from a dual placental lobe perfusion system was centrifuged to 145 
pellet fractions containing STBMV (10,000 x g) and STBEX (150,000 x g). The 146 
method has previously been described in detail by Dragovic et al[18]. A BD LSRII 147 
flow cytometer (BD Biosciences, California, USA) was used to phenotype STBMV 148 
and the NanoSight NS500 system (Malvern Instruments, Malvern, UK) was used to 149 
measure the size and concentration of STBEX using Nanoparticle Tracking Analysis 150 
(NTA). The protein concentration of isolated STBMV and STBEX was determined by 151 
the BCA protein assay and STBEV were stored at –80°C until further use. 152 
 153 
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Western blotting 154 
Western blotting was performed using placental lysate (PL, 18 µg) and STBEV (6 155 
µg) from NP and PE placentas. STBMV and STBEX were treated with HEPES lysis 156 
buffer 1:1 (50mM HEPES, pH 7.5; 2% SDS; 10% Glycerol). Western blots were 157 
incubated overnight at 4°C with mouse monoclonal anti-NEP antibody (1:1000, 158 
ab951; Abcam) and mouse monoclonal anti-placental alkaline phosphatase (PLAP) 159 
antibody (1:1000; NDOG2, in-house antibody). After incubation with HRP-conjugated 160 
anti-mouse IgG antibody (1:4000) for 1 hour at room temperature, Pierce™ ECL 161 
Western Blotting Substrate (Thermo Fisher Scientific) was used for 162 
chemiluminescence detection of antigens on x-ray film. Coomassie Brilliant Blue R-163 
250 (Bio-Rad Laboratories, California, USA) was used to stain total protein and 164 
bands were normalised to this using ImageJ version 1.51 (public domain).  165 
Immunoprecipitation 166 
Dynabeads™ Sheep-Anti Mouse IgG (50 µL; Life Technologies, California, USA) 167 
were incubated overnight at 4°C with either: anti-NEP antibody (6 µg/mL, MA1-168 
19086; Thermo Fisher Scientific), anti-PLAP antibody (6 µg/mL; NDOG2, in-house 169 
antibody) or anti-IgG1 isotype control antibody (6 µg/mL, 400153; BioLegend). 170 
STBEV from NP placentas were incubated for 10 minutes at 4°C with 10x FcR 171 
blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany). Antibody-coated 172 
Dynabeads™ were then incubated overnight at 4°C with 25 µg of blocked 173 
STBMV or STBEX in PBS. Unbound sample was washed using PBS and STBEV 174 
separated from the Dynabeads™ by reducing agent, 1x Laemmli Sample Buffer 175 
(Bio-Rad Laboratories, California, USA) and centrifugation at 13,000 RPM. 176 
Western blotting was carried out on isolated STBEV and blots were probed 177 
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using anti-NEP antibody (1:1000, ab951; Abcam) and anti-PLAP antibody 178 
(1:1000, NDOG2, in-house antibody). 179 
NEP activity of STBEV 180 
NEP activity in STBEV derived from NP placentas was determined using the 181 
SensoLyte® 520 Neprilysin Activity Assay Kit (AnaSpec, California, USA). The 182 
provided substrate, 5-FAM/QXL® FRET, was incubated with different amounts of 183 
STBEX and STBMV (10, 25 and 50 µg) for 1 hour at 37°C. Specific cleavage of 5-184 
FAM/QXL® FRET by NEP caused the release of fluorescent product, 5-FAM. 185 
Fluorescence readings were monitored at excitation/emission = 490/520 nm and 186 
accumulation of 5-FAM correlated to NEP activity. Measurements were also taken 187 
with the addition of a specific NEP inhibitor, thiorphan (0.1 µmol/L)[19]. Thiorphan 188 
dose was optimised by incubating 10 µg of STBEV with 0.025, 0.05 and 0.1 µmol/L 189 
of thiorphan prior to measuring NEP activity.  190 
Flow cytometry analysis 191 
PPP samples from women with PE and NP were matched according to gestational 192 
age. Flow cytometry was used to specifically interrogate STBMV for NEP (the 193 
protocol used has been previously described[20,21]). We have previously described 194 
in detail the measures to remove contaminants, the use of PPP for labelling with 195 
target antibody and data acquisition using appropriate control gates [22]. Alterations 196 
to our previously published method were as follows: (a) samples were stained using 197 
PLAP-PE (0.05 µg/mL; NDOG2, in-house antibody) and NEP-APC antibody (1:10, 198 
130-093-450; Miltenyi Biotec) for co-expression analysis. (b) Double positive (PLAP+ 199 
NEP+) events per mL on STBMV present in PPP were calculated. BD FACSDiva™ 200 
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8.0 (BD Biosciences, New Jersey, USA) and FlowJo® 10 (FlowJo LLC, Oregon, 201 
USA) were used for flow cytometer data acquisition and analysis.  202 
Plasma EV isolation and activity assay 203 
PPP samples from women with PE and NP were analysed together with non-204 
pregnant samples (included as an additional control). Samples were centrifuged at 205 
13,000 x g for 2 minutes to make platelet free plasma (PFP), then 300 µL of each 206 
sample was processed using Izon qEVsingle columns (Izon Science, Christchurch, 207 
New Zealand). Columns were used according to manufacturer’s guidelines and 208 
enabled EV to be purified from PFP using size exclusion chromatography. Isolated 209 
exosomes in fractions 6-8 (600 µL) were collected in PBS buffer and concentrated 210 
using Amicon Ultra-4 Centrifugal Filter Units (Merck Millipore, Massachusetts, USA). 211 
A final volume of 110 µL was then measured for NEP activity and analysed using 212 
Nanoparticle Tracking Analysis. Following the same protocol as the STBEV activity 213 
assay, duplicate readings were recorded for NEP activity in 50 µL of isolated EV. 214 
Statistical analysis 215 
Data was analysed using GraphPad Prism 7 (GraphPad Software, California, USA). 216 
Either paired Student t-test or unpaired Welch’s t-test was applied, assuming 217 
Gaussian distribution, and values were expressed as mean ± SEM.   218 
 11 
C) RESULTS 219 
Upregulated NEP expression in PE placenta and STBEV  220 
Strong NEP staining was observed on PE placental tissue (Figure 1A), compared to 221 
weak NEP staining on NP placental tissue (Figure 1B) and absent staining with 222 
control IgG1 antibody on PE placental tissue (Figure 1C). NEP expression was 223 
consistent, localised on the STB and confirmed previous results by Li et al[16]. 224 
Findings were corroborated by Western blot analysis of PE and NP placental lysate 225 
(PL); an 11-fold increase in NEP expression was detected (n=3; p<0.05, Figure 1D).  226 
Increased levels of NEP were also present in PE STBMV (2.3-fold; n=5; p<0.05; 227 
Figure 1E) and PE STBEX (4.3-fold; n=5; p<0.05, Figure 1F) derived by placental 228 
perfusion. An enrichment of NEP expression in STBEV relative to PL was also 229 
observed and all samples were positive for PLAP, an STB marker.  230 
 231 
Active NEP is co-expressed with PLAP in STBEV 232 
STBEV were isolated using either anti-PLAP or anti-NEP antibody on magnetic 233 
Dynabeads (Figure 2A). Western blot analysis identified that STBEV precipitated 234 
using anti-NEP antibody were positive for PLAP and conversely, STBEV precipitated 235 
using anti-PLAP antibody were positive for NEP (Figure 2B). This confirmed that 236 
NEP was co-expressed with PLAP on the same population of STBEV (n=3).  237 
NEP activity was quantified by measuring rate of accumulation of a substrate (5-238 
FAM); thiorphan was used as a specific NEP inhibitor. A dose response of thiorphan 239 
on NEP activity revealed an optimal concentration of 0.1umol/L (data not shown). 240 
Increasing the protein concentration of STBMV and STBEX increased NEP activity, 241 
which could be blocked with almost 100% efficacy by thiorphan (Figures 3A and 3B).  242 
 243 
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NEP positive STBMV events are significantly elevated in PE plasma 244 
PPP from women with PE and gestational age-matched NP was analysed using 245 
flow-cytometry to determine PLAP+ and NEP+ events (a gating strategy previously 246 
published by us was used to exclude EV originating from non-STB cell types [20]). 247 
We first confirmed the previously well described [23] increase in STBMV events 248 
positive for PLAP in plasma derived from PE (4,188 ± 1,157) compared to NP (1,398 249 
± 641; Figure 4A).  We found a significant increase in PLAP and NEP double positive 250 
events per mL in STBMV from PE (2,730 ± 731) compared to NP plasma (805 ± 350; 251 
p<0.05; Figure 4B).  252 
 253 
NEP activity is higher in EV isolated from PE plasma  254 
EV were isolated from PE and gestational age matched NP peripheral venous 255 
plasma (n=8) using size exclusion chromatography. NEP activity was higher in EV 256 
from PE plasma than NP (p<0.05; Figure 5A). EV purified from PFP samples of 257 
healthy, non-pregnant controls (n=3) had significantly less NEP activity than EV NP 258 
(p<0.05; Figure 5B) consistent with the latter being of placental origin.  259 
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D) DISCUSSION 260 
This study is the first to investigate peripherally circulating NEP expression and 261 
activity in PE. It demonstrates that NEP is expressed in the placenta (at the STB) 262 
and in the peripheral circulation on STBEV, where it is co-expressed with PLAP. It 263 
reports that NEP expression is upregulated in PE STBEV isolated by placental 264 
perfusion (both in STBMV and STBEX) compared to normal placentae. Moreover, it 265 
shows that circulating levels of STBMV and circulating exosomes have more NEP 266 
activity in PE. This NEP is biologically active and can be inhibited by a specific 267 
inhibitor, thiorphan. These findings are novel. Our findings corroborate an existing 268 
published report of increased NEP expression in PE syncytiotrophoblast[16]. 269 
NEP has many potential signalling functions. The most relevant to PE is enhanced 270 
degradation of multiple types of vasopeptides (including ANP, BNP, oxytocin, 271 
endothelin and bradykinin),[13,15] whose roles are normally to maintain 272 
vasodilatation, natriuresis and diuresis. As such, NEP might contribute to the 273 
defining hallmark of PE, namely hypertension, although its actions are difficult to 274 
predict given their pleotropicity. 275 
 276 
NEP inhibitors have recently been successfully trialled in combination with 277 
angiotensin inhibitors in the treatment of heart failure in non-pregnant individuals 278 
[15]. A double-blind randomised trial of a combined NEP-angiotensin inhibitor 279 
compared to angiotensin inhibitor alone was stopped early because of substantial 280 
reduction in all-cause mortality, despite the trial being powered only for 281 
cardiovascular mortality [14]. Authors hypothesised that inhibiting the broader effects 282 
of NEP in heart failure (affecting multiple vasoactive peptides) underlies its likely 283 
effect on neurohormonal systems, sodium retention and myocardial remodelling. 284 
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During normal pregnancy women also undergo significant cardiac remodelling[24]. In 285 
PE the cardiovascular burden associated with hypertension and increased peripheral 286 
resistance, imposes extra changes such that 50% of these women develop left 287 
ventricular diastolic dysfunction and a further 20% biventricular systolic dysfunction 288 
and severe left ventricular hypertrophy [7]. Some researchers believe that this 289 
cardiac dysfunction induces changes in the placenta resulting in the PE 290 
syndrome[25]. Our data convincingly show that NEP signalling via the placenta is 291 
upregulated in PE; we hypothesise that increased NEP might contribute to the 292 
cardiac remodelling seen in PE, as has been suggested by NEP inhibition outside 293 
pregnancy[15]. Further studies are required. 294 
 295 
Strengths of this study include the use of multiple experimental approaches to 296 
corroborate findings. STBEV were isolated by placental perfusion and from 297 
peripheral plasma, using differential ultracentrifugation, immunoprecipitation, size-298 
exclusion chromatography and flow cytometry. STBEV were identified at every stage 299 
using PLAP, a unique marker of trophoblast-derived material, and double-positivity 300 
for PLAP and NEP was shown bi-directionally. Moreover, biological activity of 301 
STBEV-bound NEP was confirmed in samples sourced in different ways, providing 302 
strong evidence that NEP could play a signalling role. Our study has some 303 
limitations. Our placental perfusion data show greater upregulation of NEP in PE on 304 
STBEX than STBMV. However size limitations prevent STBEX from being analysed 305 
by flow cytometry. Our size-exclusion chromatography data did not exclude non-306 
placental exosomes; thus, whilst all our data point towards STB-EX being the source 307 
of circulating NEP it is not technically possible to demonstrate this in peripheral 308 
plasma samples.  309 
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 310 
Future work should focus on the expression and role of NEP in normal pregnancy, to 311 
determine whether NEP could form part of a diagnostic or prognostic test in PE. NEP 312 
also represents a potentially exciting therapeutic target in PE, though more work is 313 
needed to determine the biological function of STBEV-bound NEP in PE on both 314 
vasoactive peptides as well as myocardial tissue. Notably, oxytocin is a recognised 315 
substrate of NEP[13]; although no studies have evaluated oxytocin levels in PE 316 
compared to normal pregnancy. Regulation of the NEP gene by histone 317 
deacetylation has been reported in the context of diabetes[26]. These authors 318 
reported an increase in cardiac NEP as a result of this. Interestingly, histone 319 
deacetylation is reported to play a role in preeclampsia by altering trophoblast cell 320 
migration[27]. It is possible that such histone deacetylation might regulate placental 321 
NEP but further work is required to elucidate this.  322 
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E) PERSPECTIVES 323 
We have demonstrated that enzymatically active NEP is released into the maternal 324 
circulation, bound to STBEV, and its expression is increased in PE. These findings 325 
raise the possibility that NEP is an important mediator between placental pathology 326 
and the maternal phenotype of PE. NEP is known to break down key vasoactive 327 
molecules such as ANP, BNP, endothelin and bradykinin, all of which have been 328 
shown to play a role in the pathogenesis of preeclampsia. These molecules are also 329 
involved in cardiovascular dysfunction, which is also a feature of preeclampsia. 330 
Clinical trials have been published demonstrating the efficacy of NEP inhibitors in 331 
both the treatment of heart failure and also of hypertension. Our findings raise the 332 
possibility of using NEP inhibitors in the treatment of preeclampsia. Additionally, 333 
identification of NEP STBEV could provide diagnostic applications.  334 
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8) NOVELTY AND SIGNIFICANCE 424 
1. What Is New? 425 
Ex vivo and circulating placental extracellular vesicles express functional neprilysin. 426 
Vesicle bound neprilysin is biologically active and can be inhibited by thiorphan (a 427 
specific neprilysin inhibitor). 428 
Placentae, microvesicles and exosomes have higher neprilysin levels/activity in 429 
women with preeclampsia compared to women with normal pregnancy. 430 
2. What Is Relevant? 431 
Neprilysin is known to play significant roles in hypertension and cardiovascular 432 
remodelling in non-pregnant individuals by breaking down vasoactive peptides. 433 
Hypertension and cardiovascular remodelling are key features of preeclampsia. 434 
Placental extracellular vesicle bound neprilysin may play a role in the pathogenesis 435 
of preeclampsia. 436 
3. Summary 437 
Our data has shown convincingly that neprilysin signalling via placental extracellular 438 
vesicles is upregulated in preeclampsia.  439 
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9) FIGURE LEGENDS 440 
Figure 1. Increased NEP expression in PE placenta shown by immunohistochemical 441 
staining of placental tissue and quantitative Western blot analysis of placental lysate 442 
(PL) and STBEV. A, Intense NEP staining localised on the surface of 443 
syncytiotrophoblast cells in PE placental tissue. B, Weak NEP staining of placental 444 
tissue from normal pregnancy (NP). C, Negative immunoreactivity of placental tissue 445 
with IgG1 control antibody. D, PL (n=3), E, STBMV (n=5), and F, STBEX (n=5) 446 
analysed for NEP (100 kDa) and PLAP (60 kDa) expression. Quantitative 447 
comparison of NEP expression in NP and PE placentas also shown (*p<0.05). Scale 448 
bar: 30 μm. 449 
 450 
Figure 2. NEP is expressed with PLAP in STBMV and STBEX. A, Schematic 451 
representation of the immunoprecipitation protocol carried out using anti-NEP 452 
antibody. The same protocol was used, substituting anti-NEP for anti-PLAP and anti-453 
IgG1 (control) to formulate the Western blot below. B, Representative immunoblot 454 
showing co-existence of NEP and PLAP in both NEP+ positive (anti-NEP) and 455 
PLAP+ (anti-PLAP) STBMV and STBEX derived from normal pregnancy (n=3). 456 
Mouse IgG1 was used as the control antibody (ctrl IgG1).  457 
 458 
Figure 3. STBMV and STBEX express active NEP. A, STBMV and B, STBEX 459 
express functional NEP, demonstrated by a dose dependent accumulation of 460 
fluorescent product, 5-FAM. Incubation with 0.1 μmol/L thiorphan resulted in a 461 
significant reduction in NEP activity (*p<0.05, **p<0.01, n=3). 462 
 463 
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Figure 4. Flow cytometry analysis of circulating STBMV in PPP collected from 464 
patients with NP (n=8) and PE (n=8). Samples connected by lines were matched by 465 
gestational age to facilitate comparison. A, PLAP positive STBMV events were 466 
higher in plasma from PE compared to NP. B, PLAP and NEP double positive 467 
STBMV events were significantly higher in plasma from PE compared to NP 468 
(*p<0.05). 469 
 470 
Figure 5. NEP activity and characterisation of EV isolated from PFP using size 471 
exclusion chromatography. A, Significantly higher NEP activity measured in 472 
exosomes from PE PFP compared to NP (n=8, *p<0.05). Samples connected by 473 
lines were matched by gestational age to facilitate comparison. B, EV from non-474 
pregnant patients (n=3) showed a significant reduction in NEP activity (*p<0.05).   475 
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10) TABLES 476 
Table 1. Clinical Characteristics of the Study Groups 477 
 
Placental EV Plasma EV 
Characteristic NP (n=5) PE (n=5) NP (n=9) PE (n=9) 
Age, y 33.0 ± 1.7 31.4 ± 2.0 29.7 ± 1.6 30.1 ± 2.3  
GA, weeks 39.6 ± 0.8 34.8 ± 1.5*  35.9 ± 0.2 35.8 ± 0.2 
Primiparous, n 0 1 5 6 
BMI, kg/m
2
 28.0 ± 3.4 31.2 ± 2.9 23.6 ± 0.6 28.7 ± 2.1‡ 
Proteinuria, mg/mmol -  232.9 ± 66.8 - 234.1 ± 84.4  
Systolic BP, mm Hg 128.4 ± 
5.1 
164.4 ± 7.3† 
 
124.7 ± 1.3 173.0 ± 4.0|| 
Diastolic BP, mm Hg 75.2 ± 0.5 102.6 ± 4.2† 
 
79.0 ± 2.3 106.9 ± 2.7|| 
Birth weight, g 3628 ± 
279 
2136 ± 400* 3544 ± 170 2618 ± 137|| 
Smoking history, n 0 0 0 1 
 478 
Data are expressed as mean ± SEM. BMI indicates body mass index; BP, blood 479 
pressure; EV, extracellular vesicles; GA, gestational age; NP, normal pregnancy; and 480 
PE, preeclampsia. *P<0.05, †P<0.01 between placental EV groups. ‡P<0.05, 481 
||P<0.01 between plasma EV groups. 482 
